Effect of Addition of Medicinal Cannabis Treatment to Conventional Treatment in Diabetic Neuropathy Patients
Journal Title: Advances in Diabetes & Endocrinology - Year 2016, Vol 1, Issue 1
Abstract
Background: Diabetic neuropathy is unfortunately the most common complication associated with a common malady increasing in prevalence by 5% a year. None of the disease-modifying drugs that have been designed to target multiple metabolic pathways has proven effective. Thus the treatment currently is mostly symptomatic. The current study assessed the ability of cannabis added to maximal conventional therapy to ameliorate diabetic neuropathy symptoms. Methods: At screening, patients were assessed for possibility of being treated by receiving cannabis therapy (CT, smoking, 20 grams per month) provided that they have completed a period of at least 12 months of optimal conventional treatment including at least one narcotic agent and at least one of following analgesic treatments: tricyclic antidepressants (amitriptyline and nortriptyline), anticonvulsants (gabapentin and pregabalin), and Serotonin- Norepinephrine Reuptake Inhibitors (SNRIs) (duloxetine and venlafaxine). Patients suitable for CT, were treated for at least 3 months more by alpha lipoic acid 600 mg, vitamin B complex, duloxetine 30 mg and tramadol 100 mg up to thrice a day. If after 3 months of treatment, the patients were still painful (BPI pain severity higher than 7) cannabis therapy was begun. Patients were followed up every 6 months for up to one year. The following Patient Reported Outcome scores (PRO’s) were collected: VAS pain intensity, VAS pain severity, BPI pain severity, BPI pain interference and SF12. Results: 89 patients were screened. 15 of them improved after 3 months of maximal conventional therapy, and thus did not meet the inclusion criteria of minimal pain severity. 74 patients begun cannabis therapy and results are available after 6 months for 73 of them and 70 patients were followed up to 12 months. 4/74 patients stopped CT (1/74 due to ileus, 3/74 due to pain resolution). BPI pain severity decreased from 9.4±0.8 to 4.3±1.7 at six months, while pain interference decreased from 8.6±1.1 to 3.7±1.6. SF12v2 Physical Compounded Score (PCS) changed from 34±8 to 46±8 at 6M. Conclusions: The addition of CT leads to substantial pain reduction accompanied by decrease in HbA1C while quality of life questionnaires scores improved. The mechanism leading to improved diabetic control is not known at this time and requires further study.
Authors and Affiliations
Dror Robinson
Keywords
Related Articles
- EP ID EP246891
- DOI 10.13188/2475-5591.1000005
- Views 135
- Downloads 0
Bravais-Jacksonian Epilepsy Associated With Type 2 Diabetes Mellitus
Introduction: Epilepsy associated with diabetes mellitus is very rare, and is seen mainly in type 1 diabetes. The focal forms are exceptional. We report an unusual observation of Bravais-Jacksonian epilepsy (BJE) in type...
New Era of Management for Diabetes and Hypertension
Looking back on the history of medical care, noteworthy diseases have changed along with long history. For recent years, metabolic syndrome (Met-S) has been increasing all over the world, which is an important health, me...
Conservative Management of Sclerosing Mucoepidermoid Carcinoma with Eosinophilia of the Thyroid Gland: 12 Years Follow-Up after an Atypical Initial Therapy
Objective: Sclerosing Mucoepidermoid Carcinomas (SMEC) are low-grade malignant tumors with both mucinous and squamous differentiation representing less than 1% of thyroid malignancies. SMEC are sometimes associated with...
New Reference Values for Thyrotropin Hormone in Diabetic Patients
Objective: The present study aimed to find out how prevalent the thyroid disorders and the association of thyroid function with cardiovascular risk factors in type 2 diabetic patients.. Material and methods: This is a re...
Diagnostic Value of Serum Adenosine Deaminase in Type II Saudi Diabetic Patients
Background: Diabetes mellitus (DM) is one of the most causative important factors of mortality in the developing countries. Adenosine deaminase (ADA) is a purine metabolizing enzyme that catalyzes the deamination of aden...